作为治疗目标的ApoC-III:它是否适合临床使用?
Marta Biolo1, Federica Galimberti2, Camilla Portinari1
1Department of Medicine - DIMED, Clinica Medica 1, University of Padova, Padua, 35128, Italy.
Current atherosclerosis reports
|July 18, 2025
概括
脂蛋白C-III (ApoC-III) 抑制策略,包括反感性寡核酸和siRNA,有效降低甘油三和降低胰腺炎风险. 需要进一步的试验来确认心血管益处.
科学领域:
- 脂质代谢和心血管疾病研究.
- 药理干预治疗高甘油三血症的方法.
背景情况:
- 阿波蛋白C-III (ApoC-III) 显著影响三糖代谢.
- 升高的ApoC-III水平与过高甘油三血症,心血管风险和急性胰腺炎有关.
研究的目的:
- 审查目前关于抑制ApoC-III的策略的证据.
- 总结新型ApoC-III降低疗法的疗效和安全性.
主要方法:
- 关于ApoC-III抑制策略的当前文献的综述.
- 对针对ApoC-III的反感性寡核酸 (ASOs) 和小干扰RNA (siRNA) 的临床试验数据的分析.
主要成果:
- 伏兰索森 (ASO) 降低了甘油三和胰腺炎的风险,但存在血小板狭窄的风险.
- 奥莱扎森 (ASO) 和普洛扎西兰 (siRNA) 显示出在降低甘油三和胆固醇性脂蛋白方面强大的有效性,并改善了安全性.
- 早期数据表明,这些药物可能会降低急性胰腺炎风险.
结论:
- 抑制ApoC-III是一种有效的方法来控制高甘油三血及其并发症.
- 奥莱扎森和普洛扎西兰显示出更广泛的临床应用的希望.
- 需要进行以结果为导向的试验,以确定ApoC-III抑制在降低心血管风险中的作用.
相关概念视频
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Therapeutic Index
5.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
5.1K
Targets for Drug Action: Overview
7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K
Atherosclerosis III: Management
36
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
36
Drug Administration and Therapy Phases: Overview
761
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
761
Direct-Acting Cholinergic Agonists: Therapeutic Uses
896
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
896

![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
